COMP <GO>
INCY vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Incyte Corp. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: INCY 7
— LLY 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: INCY
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
balance-sheet
10.04
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | 83.64% | +9.16 | INCY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.40% | 32.36% | +10.04 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 36.4x | -23.92 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 2.30% | +2.69 | INCY | /fcf-yield <GO> |
| Operating Margin | 29.50% | 40.21% | -10.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 25.00% | 31.90% | -6.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | 45.51% | -24.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 10.04 | 9.29 | +0.75 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.5 | 77.9 | -20.37 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.51 | +0.50 | INCY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.5x | 26.3x | -10.75 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.68B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | LLY REV | INCY GROSS % | LLY GROSS % | INCY FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $65.18B | 92.8% | 83.0% | $1.18B | $16.81B |
| FY 2024 | $4.24B | $45.04B | 92.6% | 81.3% | $144.5M | $8.82B |
| FY 2023 | $3.70B | $34.12B | 44.0% | 79.3% | $330.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
LLY // BETA 0.51